- uniQure N.V. (NASDAQ: QURE) fell sharply after a mixed four-year update for its Huntington's disease gene therapy.
- Fair Isaac Corporation (NYSE: FICO) dropped as investors reacted to rising competition from VantageScore in mortgage credit scoring.
- ClearPoint Neuro, Inc. (NASDAQ: CLPT) declined despite reporting revenue growth.
Today's top decliners were led by uniQure N.V. (NASDAQ: QURE), which fell 37.33% to $24.51. The decline followed mixed four-year data for AMT-130, its experimental Huntington's disease gene therapy, as reported by Investor's Business Daily. This is a stronger explanation than focusing only on law-firm investigation notices.
Fair Isaac Corporation (NYSE: FICO) dropped 26.52% to $617.87 after U.S. housing regulators moved to expand the use of VantageScore alongside FICO in mortgage pricing. The change raised concerns about FICO's long-standing market position, according to Barron's.
ClearPoint Neuro, Inc. (NASDAQ: CLPT) fell 23.12% to $11.77, even after reporting 18% year-over-year revenue growth to $10.90 million. The move suggests investors may have focused on valuation, expectations, or broader risk sentiment rather than revenue growth alone.
The Canary HBAR ETF (ARCA: HBR) declined 14.63% to $14.12, reflecting weakness in HBAR-linked exposure. GrafTech International Ltd. (NYSE: EAF) fell 14.16% to $8.55, pressured by broader headwinds in the metal fabrication and steel-related industries.
In summary, the day's losses were driven by clinical data concerns, regulatory pressure, sector weakness, and investor caution.
